-limited-logo-1200x675.png?v=20221128110814)
HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report)'s share price fell 4% on Friday . The stock traded as low as $16.20 and last traded at $16.20. 21,337 shares changed hands during mid-day trading, a decline of 82% from the average session volume of 119,082 shares. The stock had previously closed at $16.87.
Analysts Set New Price Targets
Several research firms recently issued reports on HCM. Cantor Fitzgerald restated an "overweight" rating on shares of HUTCHMED in a report on Friday, January 12th. StockNews.com upgraded shares of HUTCHMED from a "hold" rating to a "buy" rating in a report on Wednesday, March 27th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $29.70.
Read Our Latest Stock Report on HCM
HUTCHMED Stock Performance
The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.60 and a current ratio of 2.72. The stock's 50 day moving average is $15.19 and its 200 day moving average is $16.68.
Institutional Trading of HUTCHMED
Several institutional investors and hedge funds have recently bought and sold shares of the company. Capital International Investors raised its position in shares of HUTCHMED by 0.6% during the 1st quarter. Capital International Investors now owns 9,105,103 shares of the company's stock valued at $173,532,000 after buying an additional 50,212 shares in the last quarter. Goldman Sachs Group Inc. raised its position in shares of HUTCHMED by 1,096.7% during the 2nd quarter. Goldman Sachs Group Inc. now owns 3,913,287 shares of the company's stock valued at $49,464,000 after buying an additional 3,586,271 shares in the last quarter. BlackRock Inc. raised its position in shares of HUTCHMED by 3.6% during the 1st quarter. BlackRock Inc. now owns 3,516,585 shares of the company's stock valued at $66,534,000 after buying an additional 123,396 shares in the last quarter. Bellevue Group AG raised its position in shares of HUTCHMED by 62.6% during the 1st quarter. Bellevue Group AG now owns 1,750,690 shares of the company's stock valued at $33,123,000 after buying an additional 673,820 shares in the last quarter. Finally, State Street Corp raised its position in shares of HUTCHMED by 1.0% during the 3rd quarter. State Street Corp now owns 1,190,914 shares of the company's stock valued at $10,551,000 after buying an additional 11,417 shares in the last quarter. 8.82% of the stock is currently owned by hedge funds and other institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.
Read More
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
